0001469299-11-000314.txt : 20110516 0001469299-11-000314.hdr.sgml : 20110516 20110516121345 ACCESSION NUMBER: 0001469299-11-000314 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110331 FILED AS OF DATE: 20110516 DATE AS OF CHANGE: 20110516 EFFECTIVENESS DATE: 20110516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOZONE PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001412486 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 205978559 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-146182 FILM NUMBER: 11844708 BUSINESS ADDRESS: STREET 1: 4400 BISCAYNE BLVD STREET 2: SUITE 850 CITY: MIAMI STATE: FL ZIP: 33137 BUSINESS PHONE: 800-689-0930 MAIL ADDRESS: STREET 1: 4400 BISCAYNE BLVD STREET 2: SUITE 850 CITY: MIAMI STATE: FL ZIP: 33137 FORMER COMPANY: FORMER CONFORMED NAME: International Surf Resorts, Inc. DATE OF NAME CHANGE: 20070917 NT 10-Q 1 biozoneform12b25nt10q033111.htm BIOZONE FORM 12B-25 FORM 10-Q 03/31/11 biozoneform12b25nt10q033111.htm
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 12b-25

Commission File Number: 333-146182


NOTIFICATION OF LATE FILING

¨ Form 10-K                                           ¨ Form 11-K                                           ¨ Form 20-F                                           ý Form 10-Q
¨ Form N-SAR

For Period Ended: March 31, 2011

¨ Transition Report on Form 10-K                                                                           ¨ Transition Report on Form 10-Q
¨ Transition Report on Form 20-F                                                                           ¨ Transition Report on Form N-SAR

For the Transition Period Ended: _______________________________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates: _______________________________________
        ________________________________________________________________________

PART I
REGISTRANT INFORMATION

Full name of registrant                                                                Biozone Pharmaceuticals, Inc.
Former name if applicable
Address of principal executive office                                       4400 Biscayne Boulevard
City, state and zip code                                                               Miami, FL 33137


PART II
RULE 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

 
T
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form 10-Q, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 
 
1
 
PART III
NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

The compilation, dissemination and review of the information required to be presented in the Form 10-Q for the relevant quarter has imposed time constraints that have rendered timely filing of the Form 10-Q impracticable without undue hardship and expense to the registrant.  The registrant undertakes the responsibility to file such quarterly report no later than five days after its original due date.

PART IV
OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

   Roberto Prego Novo                           (800) 689-0930                                                                  
        (Name)                                                 (Area Code)          (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If the answer is no, identify report(s).

                                                        T  Yes    ¨  No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

                                                        ¨ Yes     T  No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.




 
2
 

Biozone Pharmaceuticals, Inc.
Name of Registrant as Specified in Charter.

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Dated:  May 16, 2011                                                           /s/ Roberto Prego Novo                                                      
By: Roberto Prego Novo
Title:  President
 
 
 
3